Western blot analysis was performed on Human samples (30 ug) of Alzheimer's Disease patient CSF sample (Lane 1) and corresponding normal CSF sample (Lane 2). The blots were probed with Anti-beta-Amyloid Mouse Monoclonal Antibody (Product # 13-0100Z, 2 ug/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 ug/ml, 1:2500 dilution). A ~ 110 kDa band corresponding to beta-Amyloid was observed in Alzheimer's Disease patient CSF sample and a 35 kDa band was observed across both human samples. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX) ), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with Pierce™ Power Blotter System (22834). The membrane was probed with the relevant primary and secondary Antibody using iBind™ Flex Western Starter Kit (Product # SLF2000S). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||A 28 amino acid synthetic peptide derived from the beta-amyloid peptide.|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||2 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Amyloid beta peptide is the major constituent of amyloid plaques in the brains of individuals afflicted with Alzheimer and quote;s disease. This peptide is generated from the beta-amyloid precursor protein (beta APP) in a two-step process. The first step involves cleavage of the extracellular, amino-terminal domain of beta APP. Protein cleavage is performed by an aspartyl protease termed beta-secretase (BACE). This enzyme is synthesized as a propeptide that must be modified to the mature and active form by the prohormone convertase, furin. Beta APP cleavage by the mature form of BACE results in the cellular secretion of a segment of beta APP and a membrane-bound remnant. This remnant is then processed by another protease termed gamma-secretase. Gamma-secretase cleaves an intra-membrane site in the carboxyl-terminal domain of beta APP, thus generating the amyloid beta peptide. Gamma-secretase is believed to be a multi-subunit complex containing presenilin-1 and 2 as central components. Found associated with the presenilins is the transmembrane glycoprotein nicastrin. Nicastrin has been found to bind to the carboxyl-terminus of betaAPP and helps to modulate the production of the amyloid beta peptide.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
||Inhibiting protein-amyloid interactions with small molecules: a surface chemistry approach.||Inbar P,Yang J||Bioorganic and medicinal chemistry letters (16:1076)||2006|
|Not Applicable||Not Cited||
Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
13-0100Z was used in ELISA to use intracerebroventricular injection of anti-Abeta antibody to treat murine models of Alzheimer's disease
|Chauhan NB,Siegel GJ||Expert review of vaccines (3:717)||2004|
|Human||Not Cited||Inhibiting protein-amyloid interactions with small molecules: a surface chemistry approach.||Inbar P,Yang J||Bioorganic and medicinal chemistry letters (16:1076)||2006|
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
13-0100Z was used in immunoprecipitation to examine beta-amyloid formation and its inhibition.
|Solomon B,Koppel R,Hanan E,Katzav T||Proceedings of the National Academy of Sciences of the United States of America (93:452)||1996|
|Not Applicable||Not Cited||
Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury.
13-0100Z was used in immunohistochemistry to test if caspase-3-mediated cleavage of beta-amyloid precursor protein occurs in traumatic axonal injury
|Stone JR,Okonkwo DO,Singleton RH,Mutlu LK,Helm GA,Povlishock JT||Journal of neurotrauma (19:601)||2002|